Edition:
United Kingdom

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

20.68USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$20.68
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
614,258
52-wk High
$36.63
52-wk Low
$11.66

Chart for

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $3,479.97
Shares Outstanding(Mil.): 97.18
Dividend: --
Yield (%): --

Financials

  MNK.N Industry Sector
P/E (TTM): -- 31.13 33.63
EPS (TTM): -0.15 -- --
ROI: -0.14 15.55 15.02
ROE: -0.39 16.92 16.60

Mallinckrodt to spin off generics business, but to keep options open

Mallinckrodt Plc plans to spin off its specialty generics business to shareholders by the second half of 2019, but said it was still open to a sale of the unit.

06 Dec 2018

UPDATE 3-Mallinckrodt to spin off generics business, but to keep options open

* Branded drug co will rely on Acthar for nearly 50 pct of sales

06 Dec 2018

Mallinckrodt plans to spin off specialty generics business

Dec 6 Drugmaker Mallinckrodt Plc said on Thursday it planned to spin off its specialty generics business to shareholders by the second half of 2019.

06 Dec 2018

UPDATE 2-Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK, Aug 16 The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis.

16 Aug 2018

Earnings vs. Estimates